Clinical study to investigate the potential of an engineered human monoclonal antibody, hCTM01, for targeted chemotherapy of ovarian cancer

Tumor Targeting

Volumn 3, Issue 1, 1998, Pages 55-57

  Broadhead, T J ^a   Davies, Q ^a   Van Hof, A C ^a   Molthoff, C F M ^a   Perkins, A C ^a   Roos, J C ^a   Prinssen, W M ^a   Verheijen, R H M ^a   Den Hollander, W ^a   Sopwith, M ^a   Frier, M ^a   Kenemans, P ^a   Symonds, E M ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Engineered human antibody; MUC 1 gene product; Ovarian cancer; Targeted therapy

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HCTM 01; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG LABELING; DRUG TARGETING; DRUG UPTAKE; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN TISSUE; LIVER TOXICITY; OVARY CANCER; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; TREATMENT INDICATION;

EID: 0031744820     PISSN: 13518488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)